Home > Boards > US Listed > Biotechs > Bio-Path Holdings Inc. (BPTH)

Conference call update:

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
SJSTOCKSHARK Member Profile
 
Followed By 11
Posts 1,585
Boards Moderated 1
Alias Born 09/19/06
160x600 placeholder
Bio-Path Holdings to Announce Third Quarter 2019 Financial Results on November 15, 2019 GlobeNewswire Inc. - 11/8/2019 8:00:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 11/1/2019 4:49:22 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 11/1/2019 4:46:18 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 10/22/2019 5:06:33 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/15/2019 4:24:51 PM
Bio-Path Holdings Appoints Martina Molsbergen to Board of Directors GlobeNewswire Inc. - 10/15/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/25/2019 5:17:26 PM
Bio-Path Updates Intellectual Property Portfolio with Addition of Recently Issued Second Platform Technology Patent GlobeNewswire Inc. - 9/25/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/4/2019 4:07:11 PM
Bio-Path Holdings to Present at the H.C. Wainwright 21st Annual Global Investment Conference GlobeNewswire Inc. - 9/3/2019 4:01:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/27/2019 6:02:06 AM
Bio-Path Announces Patient Dosing in Amended Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia GlobeNewswire Inc. - 8/26/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/15/2019 7:06:51 AM
Bio-Path Holdings Reports Second Quarter 2019 Financial Results GlobeNewswire Inc. - 8/15/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/14/2019 4:20:01 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/6/2019 5:07:29 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/6/2019 5:05:06 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 6/6/2019 6:01:49 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/4/2019 4:31:59 PM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 5/16/2019 4:19:14 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/16/2019 7:06:23 AM
Bio-Path Holdings Reports First Quarter 2019 Financial Results GlobeNewswire Inc. - 5/16/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/15/2019 4:32:37 PM
Bio-Path Holdings to Announce First Quarter 2019 Financial Results on May 16, 2019 GlobeNewswire Inc. - 5/10/2019 4:01:00 PM
Withdrawal of Registration Statement (rw) Edgar (US Regulatory) - 4/12/2019 5:00:51 PM
SJSTOCKSHARK   Thursday, 08/15/19 12:26:05 PM
Re: None
Post # of 6201 
Conference call update:

BPTH in first Q raised 21 million in cash of which only 17 million is left. The cash burn rate will increase to 2 million per quarter. Only 8 1/2 quarters of cash rremains.

The science continues to look good with only one more patient needed for Dasatinib/Prexigebersen safety trial to be completed. The results will be released probably in the 4th Q. The triple safety study adding Venetoclax will then begin for another 6 patients. 19 evaluable patients will again be needed for the triple study.

To me the real potential is BP-1003 which targets the stat 3 protein. Patient dosing will not begin for this drug until the second half of 2020.

PN needs to raise more cash. He should sell 1 million shares of stock now and raise 11 million This would give the company 3 1/2 years to bring a drug to market or sell the drug rights.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist